




RealRate

PHARMACEUTICAL 2021

Deciphera Pharmaceuticals Inc
Rank 114 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Deciphera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 334%, being 78% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	584,031
Cost of Goods Sold	225
Intangible Assets	0
Liabilities, Current	69,992
Liabilities, Non-Current	28,764
Other Assets	48,818
Other Compr. Net Income	-100
Other Expenses	0
Other Liabilities	0
Other Net Income	4,701
Other Revenues	42,087
Property and Equipment	9,583
Research and Development	198,970
Selling, General and Administrative Expense	114,082

Output Variable	Value in 1000 USD
Assets	642,432
Liabilities	98,756
Expenses	313,277
Revenues	42,087
Stockholders Equity	543,676
Net Income	-266,489
Comprehensive Net Income	-266,539
BaseVar	550,676
ECR before Limited Liability	248%
Economic Capital Ratio	334%